Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

In early December 2025, Novo Nordisk reported phase 3 Evoke and Evoke+ trial results showing oral semaglutide did not improve ...

Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo ...

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for ...

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) ...

Overall, Novo Nordisk A/S (NYSE:NVO) is assigned ‘Buy’ or equivalent ratings from almost 60% of the analysts, with a median ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.

Dozens of units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the FDA, according to a drug safety alert issued by the Agency.